InMode Ltd.
As of Oct 22, 2026, InMode is in Stage 3, the topping phase, now in week 4 (since Sep 30, 2026). It closed at $14.05, 15.5% below its 52-week high and below its 200-day average, which is falling.
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofr… More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is INMD early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
INMD among Medical Devices58th of 141 by relative strength
All 141 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | TXG | Stage 2 · wk 48 | 99 | −7.8% |
| 2 | RCEL | Stage 2 · wk 13 | 98 | +40.8% |
| 3 | BFLY | Stage 2 · wk 26 | 98 | −26.0% |
| 4 | HAE | Stage 2 · wk 17 | 96 | +8.7% |
| 5 | GKOS | Stage 2 · wk 25 | 96 | +15.1% |
| 6 | AXGN | Stage 3 · wk 2 | 95 | −15.3% |
| 7 | NEOG | Stage 2 · wk 14 | 95 | −11.7% |
| 8 | BVS | Stage 2 · wk 15 | 95 | +10.5% |
| …58 | INMD | Stage 3 · wk 4 | 45 | −1.0% |
InMode: quick answers
What stage is InMode in?
As of Oct 22, 2026, InMode (INMD) is in Stage 3, the topping phase. It entered Stage 3 on Sep 30, 2026 and is in week 4. What the four stages mean
Is InMode in an uptrend?
Its uptrend has stalled. InMode is in Stage 3, the topping phase that follows an advance. It trades 2.1% below its 200-day average, which is falling.
How far is InMode from its 52-week high?
InMode closed at $14.05 on Oct 22, 2026, 15.5% below its 52-week high of $16.62. Its 52-week low is $12.76.
How has InMode performed over the past year?
As of Oct 22, 2026, InMode is down 12.2% over the past year and down 5.1% so far in 2026.
Which sector and industry is InMode in?
InMode is in the Medical Devices industry, part of the Health Care sector.
About this companyHealth Care· Medical Devices
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally. It offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. The company also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions. In addition, it offers hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company sells and markets its products in the United States, Canada, the United Kingdom, Ireland, Spain, Portugal, France, Belgium, Luxemburg, Italy, Germany, Austria, Japan, Australia, and India through distributors. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. The company was incorporated in 2008 and is headquartered in Yokne'am, Israel.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.